2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1322R
    Amodiaquine dihydrochloride dihydrate (Standard) 6398-98-7 99.89%
    Amodiaquine (dihydrochloride dihydrate) (Standard) is the analytical standard of Amodiaquine (dihydrochloride dihydrate). This product is intended for research and analytical applications. Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine dihydrochloride dihydrate is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect.
    Amodiaquine dihydrochloride dihydrate (Standard)
  • HY-B1442R
    Acetylleucine (Standard) 99-15-0 98.92%
    Acetylleucine (Standard) is the analytical standard of Acetylleucine. This product is intended for research and analytical applications. Acetylleucine (N-Acetyl-DL-leucine), orally active compound, can be used for the research of acute vestibular vertigo, cerebellar ataxia and nystagmus.
    Acetylleucine (Standard)
  • HY-B1901R
    Eperisone hydrochloride (Standard) 56839-43-1 99.96%
    Eperisone (hydrochloride) (Standard) is the analytical standard of Eperisone (hydrochloride). This product is intended for research and analytical applications. Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an orally active antispastic agent with a vasodilator effect, used for the research of muscle stiffness and pain. Eperisone Hydrochloride is a potent and selectively P2X7 receptor antagonist, also shows antagonism for human P2X3. Eperisone Hydrochloride works by relaxing both skeletal muscles and vascularsmooth muscles, demonstrating a variety of effects such as reduction ofmyotonia, improvement of circulationand and suppression of the pain reflex.
    Eperisone hydrochloride (Standard)
  • HY-N0570R
    Hydroxytyrosol (Standard) 10597-60-1 99.59%
    Hydroxytyrosol (Standard) (DOPET (Standard)) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields.
    Hydroxytyrosol (Standard)
  • HY-N11229
    Butyl caffeate 22020-28-6 98.15%
    Butyl caffeate (Caffeic acid butyl ester) is a caffeic acid derivative with antioxidant activity and lipophilicity (DPPH IC50 = 14.1 μM). Butyl caffeate protects neuronal PC12 cells against oxidative stress. Butyl caffeate can be used for oxidative stress related and neurodegenerative diseases research.
    Butyl caffeate
  • HY-N1414A
    3′,6-Disinapoylsucrose 76656-80-9 98.88%
    3′,6-Disinapoylsucrose is a type of oligosaccharide that's effective when taken orally, and it has antidepressant, anti-anxiety, and antioxidant properties. 3′,6-Disinapoylsucrose inhibits neuronal apoptosis by lowering the ratio of Bax to Bcl-2 in hippocampal neurons, and it enhances cognitive function in APP/PS1 transgenic mice by activating the CREB/BDNF signaling pathway.
    3′,6-Disinapoylsucrose
  • HY-N15339
    Convolamine 500-56-1 99.89%
    Convolamine is an alkaloid found in Convolvulus pluricaulis and an effective positive modulator of the sigma-1 receptor (IC50 = 289 nM), exhibiting cognitive and neuroprotective properties.
    Convolamine
  • HY-N16499
    Hericene A 157207-54-0 99.08%
    Hericene A is an orally active aromatic hericene derivative. Hericene A exhibits anti-inflammatory and neurotrophic activities, and can found in the fruiting bodies of Hericium erinaceus. Hericene A inhibits the secretion of pro-inflammatory mediators. Hericene A promotes axonal growth, neurite branching, neurotrophic factor expression and downstream signal transduction. Hericene A can be used for the research of inflammatory and neurological diseases.
    Hericene A
  • HY-N5060S
    Estragole-d4 1335401-40-5 99.9%
    Estragole-d4 is deuterated labeled Estragole (HY-N5060). Estragole (4-Allylanisole) is a relatively nontoxic volatile terpenoid ether and major component of the essential oil from many plants. Estragole significantly triggers Apoptosis, suppresses LPS-induced intracellular ROS production. Estragole activats Nrf-2 and regulates NF-κB. Estragole has anti-toxoplasma, anti-inflammatory, anti-edema, antioxidant and immunomodulatory properties. Estragole blocks DRG neuron excitability. Estragole has improves gastric ulcer activity[10].
    Estragole-d4
  • HY-P3877A
    (Leu31,Pro34)-Peptide YY (human) TFA 98.63%
    (Leu31,Pro34)-Peptide YY (human) (TFA) is the TFA form of (Leu31,Pro34)-Peptide YY (human) (HY-P3877). (Leu31,Pro34)-Peptide YY (human) (TFA) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y1 agonist with a KD of 1.0 nM.
    (Leu31,Pro34)-Peptide YY (human) TFA
  • HY-P4742A
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research.
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA
  • HY-P4886A
    Amyloid β-Protein (3-42) TFA 99.20%
    Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).
    Amyloid β-Protein (3-42) TFA
  • HY-P6437A
    Drp1 peptide inhibitor P110 TFA 99.11%
    Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.
    Drp1 peptide inhibitor P110 TFA
  • HY-U00251
    KFM19 133058-72-7 99.44%
    KFM19 is a potent, selective Adenosine receptor (A1-receptor) antagonist, with an IC50 of 50 nM.
    KFM19
  • HY-U00281
    S16961 153874-14-7 99.85%
    S16961 is a nicotinic receptor agonist.
    S16961
  • HY-Y0258S
    Benzocaine-d4 342611-08-9 99%
    Benzocaine-d4 is the deuterium labeled Benzocaine (HY-Y0258). Benzocaine is an orally active local anesthetic. Benzocaine non-competitively inhibits the binding of Ca-ATPase to Ca2+, with an IC50 of 47.1 mM. Benzocaine exerts anesthetic effects by blocking voltage-gated sodium channels. Benzocaine induces methemoglobinemia in various experimental animals.
    Benzocaine-d4
  • HY-Y0511R
    N,N-Dimethylglycine (Standard) 1118-68-9 99.84%
    N,N-Dimethylglycine (Dimethylglycine) (Standard) is the analytical standard of N,N-Dimethylglycine (HY-Y0511). This product is intended for research and analytical applications. N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects.
    N,N-Dimethylglycine (Standard)
  • HY-100634S
    4-Hydroxypropranolol-d7 hydrochloride 1219804-03-1 98.68%
    4-Hydroxypropranolol-d7 (hydrochloride) is a deuterium labeled 4-Hydroxypropranolol hydrochloride. 4-Hydroxypropranolol hydrochlorid is an active metabolite of Propranolol, with potency comparable to Propranolol. 4-Hydroxypropranolol hydrochlorid inhibits β1- and β2-adrenergic receptors with pA2 values of 8.24 and 8.26, respectively. 4-Hydroxypropranolol hydrochlorid has intrinsic sympathomimetic activity, membrane stabilizing activity and potent antioxidant properties.
    4-Hydroxypropranolol-d7 hydrochloride
  • HY-10585AR
    Valproic acid sodium (Standard) 1069-66-5 98.92%
    Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
    Valproic acid sodium (Standard)
  • HY-108506R
    Licarbazepine (Standard) 29331-92-8 99.90%
    Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
    Licarbazepine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity